SEC Form 4 · accession 0001209191-17-046025
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 8,979 | $91.05 | A | 114,990 | D | |
| Common Stock | Jul 19, 2017 | M | 20,000 | $81.54 | A | 134,990 | D | |
| Common Stock | Jul 19, 2017 | S | 28,979 | $161.00 | D | 106,011 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | Jul 19, 2017 | M | 8,979 | D | — | Feb 1, 2026 | Common Stock | 8,979 | 19,756 | D |
| Stock Option (Right to Buy)F3 | $81.54 | Jul 19, 2017 | M | 20,000 | D | — | May 31, 2023 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 02/02/2016.
- F3Fully vested.